Res Publica - Journal of Undergraduate Research
Abstract
As prescription drug prices in the United States continue to climb, the debate surrounding cost control methods has taken center stage among politicians, providers, insurance companies, and consumers alike. At the heart of this issue lies the Pharmacy Benefit Manager (PBM). These third party companies were initially intended to drive drug prices down by negotiating for benefits on behalf of clients; but their hidden business strategies and oligopolistic market share has resulted in many Americans today struggling with unfair drug costs and fewer choices of treatment. In this paper, I seek to demonstrate that by expanding PBM market competition and ensuring their overall accountability through federal regulation, we can optimize pharmaceutical reimbursements and reduce the cost share of prescription drugs for the consumer. In turn, this will allow for more Americans to receive the medication they need, when they need it - without unnecessary expenses.
Recommended Citation
Webster, Cayden (2026) "Pharmacy Benefit Managers and the Fight for Affordable Prescription Drugs: A Case for Accountability through Regulation," Res Publica - Journal of Undergraduate Research: Vol. 30Available at: https://digitalcommons.iwu.edu/respublica/vol30/iss1/8